Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Genome Therapeutics

Executive Summary

Genome Therapeutics: Files registration statement for 2 mil. share secondary offering of common stock, the Waltham, Mass.-based gene discovery company announces Jan. 10. Oppenheimer & Co. is the underwriter and has an over- allotment option of 300,000 shares. Genome intends to use net proceeds to fund R&D, particularly to accelerate human gene discovery programs, and for general corporate purposes, including working capital...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts